Clinical utility of vandetanib in the treatment of patients with advanced medullary thyroid cancer
Hari Deshpande1,3, Vicky Marler3, Julie Ann Sosa2,31Department of Medicine, 2Department of Surgery, Yale University School of Medicine, 3Yale Cancer Center, New Haven, CT, USAAbstract: Vandetanib (ZD6474) became the first systemic agent to be approved for the treatment of metastatic or locally advan...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2011-12-01
|
| Series: | OncoTargets and Therapy |
| Online Access: | http://www.dovepress.com/clinical-utility-of-vandetanib-in-the-treatment-of-patients-with-advan-a8830 |